6月5日，生物制药公司传奇生物于纳斯达克全球精选市场成功上市，共募资约4.238亿美元。科律律师事务所、君合律师事务所作为发行人律师参与交易；美国达维律师事务所、竞天公诚律师事务所则为承销商提供法律意见。
衡力斯律师事务所就开曼群岛法律提供意见；美国众达律师事务所则代表控股股东金瑞斯生物科技参与交易。
成立于2014年，传奇生物是一家临床阶段的生物制药研发企业，在美国、中国和欧洲从事针对肿瘤和其他适应症的新型细胞疗法的研发。传奇生物为香港上市公司金斯瑞生物科技的控股子公司，此次为分拆赴美上市。
此次上市联合承销商为摩根士丹利、摩根大通和杰富瑞。
君合团队牵头律师为合伙人王毅、李辰亮；科律团队牵头律师为合伙人Divakar Gupta、Richard C. Segal、Robert W. Phillips、蔡华、余仙、陆培祥；达维团队牵头律师为合伙人 Richard D. Truesdell Jr.、褚洋，同时得到合伙人Patrick E. Sigmon和David R. Bauer协助；众达团队牵头律师为合伙人周致聪、Alan Seem；衡力斯团队牵头律师为合伙人吴洛汶。
Legal Giants on Legend Biotech’s $423.8 mln U.S. IPO
Cooley and JunHe have advised Chinese biotech company Legend Biotech on its $423.8 million Nasdaq initial public offering, with Davis Polk & Wardwell and Jingtian & Gongcheng advising the underwriters.
Founded in 2014, Legend Biotech is a Nanjing-based company focusing on cell therapies for oncology and other indications. The company is owned by Hong Kong-listed Genscript Biotech.
Harney Westwood & Riegels acted as Cayman Islands legal counsel, and the company’s controlling shareholder GenScript was represented by Jones Day.
Morgan Stanley, J.P. Morgan and Jefferies were joint underwriters.
The JunHe team was led by partners Wang Yi and Li Chenliang.
Cooley was led by partners Divakar Gupta, Richard Segal, Robert Phillips, Will Cai, Michael Yu and Patrick Loofbourrow.
The Davis Polk team included partners Richard D. Truesdell Jr. and Chu Yang, with assistance from partners Patrick E. Sigmon and David R. Bauer.
Partners Charles Chau and Alan Seem led the Jones Day team.
Meanwhile, the Harneys team was led by Partner Raymond Ng.
To contact the editorial team, please email ALBEditor@thomsonreuters.com.
